Noel Donnelly
Director of Finance/CFO at PEPGEN INC.
Net worth: - $ as of 29/04/2024
Profile
Noel Donnelly is currently the Chief Financial Officer at PepGen Inc. He previously worked as the Chief Financial Officer at EIP Pharma, Inc. from 2019 to 2021.
He holds an MBA from Babson College and an undergraduate degree from the University of Massachusetts Lowell.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PEPGEN INC.
-.--% | 30/03/2024 | 0 ( -.--% ) | - $ | 29/04/2024 |
Noel Donnelly active positions
| Companies | Position | Start |
|---|---|---|
| PEPGEN INC. | Director of Finance/CFO | 30/09/2021 |
Former positions of Noel Donnelly
| Companies | Position | End |
|---|---|---|
EIP Pharma, Inc.
 EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Director of Finance/CFO | 30/09/2021 |
Training of Noel Donnelly
| Babson College | Masters Business Admin |
| University of Massachusetts Lowell | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PEPGEN INC. | Health Technology |
| Private companies | 1 |
|---|---|
EIP Pharma, Inc.
EIP Pharma, Inc. BiotechnologyHealth Technology EIP Pharma, Inc. engages in the research and development of therapeutic drugs for the central nervous system disorders. It focuses on neflamapimod, which is a clinical-stage oral investigational drug for the treatment of brain diseases such as Alzheimer?s disease and for non-brain disorders including rheumatoid arthritis. The company was founded by John Alam and Sylvie Louise Gregorie and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Noel Donnelly
